273 related articles for article (PubMed ID: 30637900)
1. Androgen deprivation therapy for prostate cancer and risk of dementia.
Robinson D; Garmo H; Van Hemelrijck M; Damber JE; Bratt O; Holmberg L; Wahlund LO; Stattin P; Adolfsson J
BJU Int; 2019 Jul; 124(1):87-92. PubMed ID: 30637900
[TBL] [Abstract][Full Text] [Related]
2. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
3. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
4. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.
Krasnova A; Epstein M; Marchese M; Dickerman BA; Cole AP; Lipsitz SR; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Mucci LA; Sun M; Trinh QD
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):410-418. PubMed ID: 31784699
[TBL] [Abstract][Full Text] [Related]
5. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
6. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.
Chung SD; Lin HC; Tsai MC; Kao LT; Huang CY; Chen KC
Andrology; 2016 May; 4(3):481-5. PubMed ID: 27062333
[TBL] [Abstract][Full Text] [Related]
8. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study.
Klil-Drori AJ; Santella C; Tascilar K; Yin H; Aprikian A; Azoulay L
Drug Saf; 2019 Aug; 42(8):1005-1011. PubMed ID: 31240687
[TBL] [Abstract][Full Text] [Related]
9. Association Between Androgen Deprivation Therapy and Risk of Dementia.
Nead KT; Gaskin G; Chester C; Swisher-McClure S; Leeper NJ; Shah NH
JAMA Oncol; 2017 Jan; 3(1):49-55. PubMed ID: 27737437
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.
Nead KT; Sinha S; Nguyen PL
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):259-264. PubMed ID: 28349979
[TBL] [Abstract][Full Text] [Related]
11. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
12. Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania.
Drevinskaite M; Patasius A; Kincius M; Urbonas V; Smailyte G
BMJ Open; 2021 Jul; 11(7):e045797. PubMed ID: 34321292
[TBL] [Abstract][Full Text] [Related]
13. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
Baik SH; Kury FSP; McDonald CJ
J Clin Oncol; 2017 Oct; 35(30):3401-3409. PubMed ID: 28841388
[TBL] [Abstract][Full Text] [Related]
14. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).
Wallander M; Axelsson KF; Lundh D; Lorentzon M
Osteoporos Int; 2019 Jan; 30(1):115-125. PubMed ID: 30324413
[TBL] [Abstract][Full Text] [Related]
15. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
[TBL] [Abstract][Full Text] [Related]
16. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
Sari Motlagh R; Quhal F; Mori K; Miura N; Aydh A; Laukhtina E; Pradere B; Karakiewicz PI; Enikeev DV; Deuker M; Shariat SF
J Urol; 2021 Jan; 205(1):60-67. PubMed ID: 32856962
[TBL] [Abstract][Full Text] [Related]
17. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.
O'Farrell S; Sandström K; Garmo H; Stattin P; Holmberg L; Adolfsson J; Van Hemelrijck M
BJU Int; 2016 Sep; 118(3):391-8. PubMed ID: 26497726
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer.
Khosrow-Khavar F; Rej S; Yin H; Aprikian A; Azoulay L
J Clin Oncol; 2017 Jan; 35(2):201-207. PubMed ID: 27870566
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
